Literature DB >> 9804860

Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes.

R S Mani1, J R Hammond, J M Marjan, K A Graham, J D Young, S A Baldwin, C E Cass.   

Abstract

The equilibrative nucleoside transporters (ENTs) are a newly recognized family of membrane proteins of which hENT1 is the nitrobenzylmercaptopurine ribonucleoside (NBMPR)-sensitive (es) and hENT2 the NBMPR-insensitive (ei) transporter of human cells. BeWo cells exhibit large numbers (>10(7)/cell) of NBMPR-binding sites and high es and ei nucleoside transport activities relative to other cell types. In this work, we have demonstrated that proliferating BeWo cells possess (i) mRNA encoding hENT1 and hENT2 and (ii) hENT1-specific immunoepitopes. We examined NBMPR binding and its inhibition of uridine transport in various BeWo membrane fractions and proteoliposomes derived therefrom to determine if NBMPR binding to intracellular membranes represented interaction with functional es transporters. Unfractionated membranes and fractions enriched 5-fold in plasma membranes relative to postnuclear supernatants exhibited high NBMPR binding activity. Intact nuclei and nuclear envelopes also exhibited abundant quantities of NBMPR-binding sites with affinities similar to those of enriched plasma membranes (Kd = 0.4-0.9 nM). When proteoliposomes were made from octyl glucoside-solubilized membranes, high affinity NBMPR-binding sites were not only observed in crude membrane preparations and plasma membrane-enriched fractions but also in nuclear envelope fractions. Proteoliposomes prepared from either unfractionated membranes or nuclear envelopes exhibited both hENT1-mediated (82-85%) and hENT2-mediated (15-18%) transport of [3H]uridine. These results provided evidence for the presence of functional es and ei transporters in nuclear membranes and endoplasmic reticulum, suggesting that hENT1 and hENT2 may function in the translocation of nucleosides between the cytosol and the luminal compartments of one or both of these membrane types.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804860     DOI: 10.1074/jbc.273.46.30818

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  The role of transporters in the toxicity of nucleoside and nucleotide analogs.

Authors:  Christopher A Koczor; Rebecca A Torres; William Lewis
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-04-18       Impact factor: 4.481

Review 2.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Low-affinity uptake of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (4-Di-1-ASP) in BeWo cells.

Authors:  Erik Rytting; Jordan Bryan; Marylee Southard; Kenneth L Audus
Journal:  Biochem Pharmacol       Date:  2006-12-01       Impact factor: 5.858

4.  Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir.

Authors:  Natalia Grañé-Boladeras; Christopher M Spring; W J Brad Hanna; Marçal Pastor-Anglada; Imogen R Coe
Journal:  Cell Mol Life Sci       Date:  2016-06-06       Impact factor: 9.261

Review 5.  Targeted heat shock protein 72 for pulmonary cytoprotection.

Authors:  Missag H Parseghian; Stephen T Hobson; Richard A Richieri
Journal:  Ann N Y Acad Sci       Date:  2016-05-06       Impact factor: 5.691

6.  Cardioprotective Effects of HSP72 Administration on Ischemia-Reperfusion Injury.

Authors:  Takashi Tanimoto; Missag H Parseghian; Takehiro Nakahara; Hideki Kawai; Navneet Narula; Dongbin Kim; Robert Nishimura; Richard H Weisbart; Grace Chan; Richard A Richieri; Nezam Haider; Farhan Chaudhry; Glenn T Reynolds; John Billimek; Francis G Blankenberg; Partho P Sengupta; Artiom D Petrov; Takashi Akasaka; H William Strauss; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2017-09-19       Impact factor: 24.094

7.  Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q).

Authors:  M F Vickers; R S Mani; M Sundaram; D L Hogue; J D Young; S A Baldwin; C E Cass
Journal:  Biochem J       Date:  1999-04-01       Impact factor: 3.857

8.  Subtype-specific regulation of equilibrative nucleoside transporters by protein kinase CK2.

Authors:  Meaghan Stolk; Elizabeth Cooper; Greg Vilk; David W Litchfield; James R Hammond
Journal:  Biochem J       Date:  2005-03-01       Impact factor: 3.857

9.  Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain.

Authors:  A Kiss; K Farah; J Kim; R J Garriock; T A Drysdale; J R Hammond
Journal:  Biochem J       Date:  2000-12-01       Impact factor: 3.857

10.  Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cells.

Authors:  Richard G E Archer; Václav Pitelka; James R Hammond
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.